Anebulo Pharmaceuticals Inc

NASDAQ ANEB

Download Data

Anebulo Pharmaceuticals Inc Price to Earnings Ratio (P/E) on June 03, 2024: -22.24

Anebulo Pharmaceuticals Inc Price to Earnings Ratio (P/E) is -22.24 on June 03, 2024, a -288.31% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.
  • Anebulo Pharmaceuticals Inc 52-week high Price to Earnings Ratio (P/E) is -4.74 on June 26, 2023, which is 78.70% above the current Price to Earnings Ratio (P/E).
  • Anebulo Pharmaceuticals Inc 52-week low Price to Earnings Ratio (P/E) is -31.11 on May 10, 2024, which is -39.88% below the current Price to Earnings Ratio (P/E).
  • Anebulo Pharmaceuticals Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -9.47.
NASDAQ: ANEB

Anebulo Pharmaceuticals Inc

CEO Dr. Joseph F. Lawler M.D., Ph.D.
IPO Date May 7, 2021
Location United States
Headquarters 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734
Employees 2
Sector Healthcare
Industry Biotechnology
Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email